Related Experiment Video
Updated: May 20, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes
Michal Piechota1, Anna Banaszewska, Joanna Dudziak
1Department of Animal Physiology and Development, Faculty of Biology, Adam Mickiewicz University, Umultowska 89 Str., 61-614 Poznan, Poland. piechota@amu.edu.pl
Insights
Scavenger receptors CD36 and MSR1 are significantly elevated in monocytes of patients with Acute Coronary Syndromes (ACS). Treatment with atorvastatin reduced the expression of these receptors, suggesting their role in ACS development.
Area of Science:
- Cardiovascular Medicine
- Immunology
- Molecular Biology
Background:
- Acute Coronary Syndromes (ACS) result from reduced coronary artery circulation, often due to plaque rupture and subsequent blood clots.
- Scavenger receptors are implicated in atherosclerosis, but their role in human ACS development is not fully understood.
Purpose of the Study:
- To investigate the expression of scavenger receptors CD36 and MSR1 in monocytes of ACS patients.
- To assess changes in CD36 and MSR1 expression after 6 months of treatment.
Main Methods:
- Real-time PCR and flow cytometry were used to analyze CD36 and MSR1 expression in monocytes.
- Blood lipid, glucose, and inflammatory markers were measured.
- Statistical analyses included Mann Whitney and Wilcoxon tests.
Main Results:
- Monocytes from ACS patients showed significantly higher CD36 and MSR1 mRNA and surface expression.
- Atorvastatin treatment led to a significant decrease in CD36 and MSR1 expression after 6 months.
Conclusions:
- Elevated CD36 and MSR1 expression in monocytes is associated with Acute Coronary Syndromes.
- These scavenger receptors are likely involved in the development and progression of ACS.
- Atorvastatin may modulate ACS progression by reducing CD36 and MSR1 expression.
Abstract:
Acute Coronary Syndromes (ACS) are a group of disorders caused by the significant reduction of circulation in coronary arteries. The most common reason of the dysfunction is a blood clot formed in place of plaque rupture. The role of scavenger receptors in development and progression of atherosclerosis has been confirmed in many animal experiments, however the knowledge about contribution of the receptors in the development of ACS symptoms in humans still remains insufficient. The aim of this work was to define the expression of two scavenger receptors: CD36 and MSR1 in monocytes of patients with ACS after the onset of symptoms and after the 6 months of treatment. The analysis of CD36 and MSR1 expression was carried out with the use of real-time PCR and flow cytometry. Analyses of lipid and glucose concentration in blood and the level of inflammatory markers in plasma were performed additionally for all ACS patients. All data obtained during the research were analyzed using statistical tests, such as Mann Whitney test, Wilcoxon test, or correlation. In all patients with symptoms of ACS the amount of CD36 and MSR1 mRNA in circulating monocytes, as well as the density of both receptors on the cells surface was significantly higher. Re-analysis of subjects after 6 months of treatment, showed a significant decrease in the CD36 and MSR1 expression in all patients who received atorvastatin. The results of presented studies demonstrate that both investigated receptors are involved in the development and/or progression of ACS.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies

